Larimar Therapeutics, Inc. LRMR

Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measuresHigh patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in screening as of month-end Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion

Larimar Therapeutics Inc. (NASDAQ:LRMR) is one of the 10 best stocks under $10 that could triple. On June 29, Larimar Therapeutics Inc. (NASDAQ:LRMR) filed the first module of its Biologics License Application (BLA) to the U.S. FDA to get its Nomlabofusp therapy approved on an accelerated basis. The company also plans to submit the other […]

The shares were acquired in multiple transactions at prices ranging from $3.33 to $3.35 per share.

Larimar Therapeutics, Inc. (NASDAQ:LRMR) is one of the Best Small-Cap Growth Stocks to Invest In Now. Recently, on June 19, Samantha Semenkow, an analyst from Citi, maintained a Buy rating on Larimar Therapeutics, Inc. (NASDAQ:LRMR), with a price target of $14. ​The firm noted that the bullish sentiment is based on the company’s lead drug […]

H.C. Wainwright initiated coverage of Larimar with a ‘Buy’ rating and a $10 price target on Thursday.

Larimar Therapeutics (NASDAQ:LRMR) shares declined 17% on Monday after the company released new data from its ongoing open-label study and confirmed the submission of the first section of its rolling Biologics License Application (BLA) seeking accelerated approval for nomlabofusp as a treatment for Friedreich’s ataxia. The biotechnology company said the initial BLA module has been submitted to the U.

Larimar submitted the module of a rolling biologics license application to the U.S. Food and Drug Administration for the accelerated approval of nomlabofusp for Friedreich’s ataxia.

Larimar Therapeutics (LRMR) said Monday that it has filed the first module of its rolling Biologics

FDA alignment on submission of BLA data package in multi-disciplinary Type B pre-BLA meeting minutes; first module of rolling BLA submitted with remaining modules expected 2H 2026Daily nomlabofusp increased and sustained skin FXN levels at 1 year and 18 months; 100% (9/9) of participants achieved and maintained levels over 50% of mean levels in healthy volunteers (comparable to asymptomatic heterozygous carriers) at 1-year Continued directional improvement across mFARS, FARS-ADL, 9-HPT, MFIS obs

Webcast on Monday, June 29, 2026, at 7:45 am ET BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host an investor event to discuss updates for the Company’s nomlabofusp clinical development program including a regulatory update and data from the ongoing long-term open label study for the treatment of Fried

The United States market remained flat over the last week but has shown a strong performance with a 24% increase over the past year, and earnings are forecast to grow by 19% annually. In this context, identifying high growth tech stocks involves looking for companies that not only align with these optimistic earnings forecasts but also demonstrate robust innovation and adaptability in an ever-evolving industry landscape.